Fig. 3: Target engagement and pharmacodynamics.
a, Target engagement as measured by the adjusted mean change from baseline (±s.e.) in the CSF levels of unbound N-terminal tau. b, Pharmacodynamics as measured by the adjusted mean change from baseline (±s.e.) in the CSF levels of p-tau181. c, Pharmacodynamics as measured by the adjusted mean change from baseline (±s.e.) in the CSF levels of total tau. d, Pharmacodynamics as measured by the adjusted mean change from baseline (±s.e.) in the CSF levels of Aβ42. Sample sizes for each group at each time point are listed for each panel. In a, the asterisks denote a significant difference from placebo for the group of the same color (***P < 0.0001). In b, the asterisks denote a statistically significant difference between the high-dose and placebo groups at week 76 (**P = 0.0022). In c, the asterisks denote a statistically significant difference between the 125 mg q4w low-dose group and the placebo group (*P = 0.0138) and between the intermediate-dose and high-dose groups at week 76 (***P < 0.0001). Analyses were two-sided at a 5% significance level. No adjustments were made for multiple comparisons.
